{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/antiplatelet-treatment/prescribing-information/ticagrelor/","result":{"pageContext":{"chapter":{"id":"92100407-8f08-53c0-8df1-1e802f4dcbe9","slug":"ticagrelor","fullItemName":"Ticagrelor","depth":2,"htmlHeader":"<!-- begin field 458ff674-0182-45ce-8605-a781008ededa --><h2>Ticagrelor</h2><!-- end field 458ff674-0182-45ce-8605-a781008ededa -->","summary":"","htmlStringContent":"<!-- begin item 9326083d-450e-4275-b59b-a781008edd70 --><!-- end item 9326083d-450e-4275-b59b-a781008edd70 -->","topic":{"id":"86dfa76b-bc1a-5d4b-bf7c-018d5d031947","topicId":"a68e1521-d84e-4abb-bb17-6186ba7a891a","topicName":"Antiplatelet treatment","slug":"antiplatelet-treatment","lastRevised":"Last revised in August 2020","chapters":[{"id":"af85e41e-4007-5daa-bc95-35aa03621ea0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"db8ef934-0123-530e-9f34-52d23ea99e56","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ebaf9360-bb92-51bc-8aba-ac3293fa1416","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b34f13e6-85f8-5c85-b2f7-5678c0779a07","slug":"changes","fullItemName":"Changes"},{"id":"9532ea0d-f7f7-5a08-9076-dedbf78ca97d","slug":"update","fullItemName":"Update"}]},{"id":"0370616e-85d0-5654-b5ad-ea9980ad8eaa","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"24bebba9-1157-505c-834d-bf255dd856a9","slug":"goals","fullItemName":"Goals"},{"id":"b1ab86f3-b045-5a24-b8ea-506ae6fa94c8","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cb61b0c8-a7f6-5e31-af33-9c4ade31a493","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"19dcf0a2-d60c-5fe4-94b7-d902d7cc17f8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"758947ec-f9bc-59c9-a07f-663f738f5428","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8c16356c-f5cf-54fc-99e8-ccc08af83ec7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"30e0cacd-1816-520e-8f4a-aba760ce71f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9e23a119-ae6d-5e11-9691-ed23c4016c39","slug":"definition","fullItemName":"Definition"},{"id":"2ef5b7fd-3211-5769-8a72-083d9f8c40c8","slug":"mechanism-of-action","fullItemName":"Mechanism of action"},{"id":"ef9f4561-2787-59c9-974b-b656929c553c","slug":"indications","fullItemName":"Indications"},{"id":"7692771a-8763-57f6-b4fe-d4711f820cfb","slug":"complications","fullItemName":"Complications"}]},{"id":"d31d1a85-d8c2-5598-b7e0-e8b2da36e45c","fullItemName":"Management","slug":"management","subChapters":[{"id":"81844a0f-b280-563a-b66c-4a5dba6e1e9c","slug":"primary-prevention-of-cvd","fullItemName":"Scenario: Primary prevention of CVD"},{"id":"c2fb4ffa-788d-5d77-a694-3e30c3008d35","slug":"secondary-prevention-of-cvd","fullItemName":"Scenario: Secondary prevention of CVD"}]},{"id":"85828cd6-6943-58a7-9657-71760be76497","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d408bf47-147e-5914-ab35-c4142ec2a33e","slug":"low-dose-aspirin","fullItemName":"Low dose aspirin"},{"id":"4098d4bf-7db2-5e79-bdec-17a2bbfaca6a","slug":"clopidogrel","fullItemName":"Clopidogrel"},{"id":"d5d8e5ca-9f57-5ac9-955b-614b85700f3e","slug":"dipyridamole","fullItemName":"Dipyridamole"},{"id":"52159350-4f8e-536b-99c4-a75908d6233a","slug":"prasugrel","fullItemName":"Prasugrel"},{"id":"92100407-8f08-53c0-8df1-1e802f4dcbe9","slug":"ticagrelor","fullItemName":"Ticagrelor"}]},{"id":"ec007ae2-2b14-50b1-a091-3875c81c5adb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f54cfffb-be9e-5523-a47f-c1100845c9c4","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4ce7f1c7-df35-54c7-9f8b-b1aefe5762f1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f4d603b9-b19a-53ac-8058-8c414be0a10b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"69fb4d5c-2946-5ef6-8c7f-b5f81dd52f9c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d1e16069-862f-500a-9f58-e84cb201da64","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fab694fa-9176-5402-b7b5-729a22dd611f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3852e22b-c968-5afe-81be-ac1efce390da","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"85828cd6-6943-58a7-9657-71760be76497","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"041745fc-7bb4-5c07-86f8-377661b3abf3","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 648245e7-f373-4479-af63-a78100915973 --><h3>Contraindications and cautions</h3><!-- end field 648245e7-f373-4479-af63-a78100915973 -->","summary":"","htmlStringContent":"<!-- begin item 78952e91-8118-4f49-b459-a78100915864 --><!-- begin field 23451a86-a61f-457a-981a-a78100915973 --><ul><li><strong>Do not prescribe ticagrelor to people with:</strong><ul><li>Actively pathological bleeding.</li><li>A history of intracranial haemorrhage.</li><li>Moderate or severe hepatic impairment.</li></ul></li><li><strong>Prescribe ticagrelor with caution to people:</strong><ul><li>A history of asthma or chronic obstructive pulmonary disease.</li><li>A history of hyperuricaemia.</li><li>At increased risk of bleeding (for example, from recent trauma, surgery, gastrointestinal bleeding, coagulation disorders).</li><li>At increased risk of bradycardia, with sick sinus syndrome, second- or third-degree AV block (unless a pacemaker is fitted).</li><li>Taking drugs that increase the risk of bleeding.</li><li>Undergoing elective surgery — discontinue 5 days before if antiplatelet effect is not desirable.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2018b</a>] </p><!-- end field 23451a86-a61f-457a-981a-a78100915973 --><!-- end item 78952e91-8118-4f49-b459-a78100915864 -->","subChapters":[]},{"id":"66cdb3d7-974b-526f-9baf-d8ac062f1894","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field e7d4030b-2bd3-41bf-a889-a781009176da --><h3>Adverse effects </h3><!-- end field e7d4030b-2bd3-41bf-a889-a781009176da -->","summary":"","htmlStringContent":"<!-- begin item c614fdbe-5688-4100-8c04-a781009175f7 --><!-- begin field aa8a1865-e406-4e79-a434-a781009176da --><ul><li><strong>Gastrointestinal (GI) </strong>— GI haemorrhage, diarrhoea, nausea, dyspepsia, constipation (common); retroperitoneal haemorrhage (uncommon).</li><li><strong>Metabolism and nutrition</strong> — hyperuricaemia (very common); gout, gouty arthritis (common).</li><li><strong>Nervous system</strong> — dizziness, syncope, headache (common); intracranial haemorrhage (uncommon).</li><li><strong>Respiratory </strong>— dyspnoea (very common); respiratory system bleedings (common).</li><li><strong>Other adverse effects include: </strong><ul><li>Confusion.</li><li>Creatinine level increases.</li><li>Eye haemorrhage.</li><li>Hypotension.</li><li>Subcutaneous or dermal bleeding, rash pruritus.</li><li>Urinary tract bleeding.</li><li>Vertigo, ear haemorrhage.</li><li>Thrombotic thrombocytopenic purpura</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>]</p><!-- end field aa8a1865-e406-4e79-a434-a781009176da --><!-- end item c614fdbe-5688-4100-8c04-a781009175f7 -->","subChapters":[]},{"id":"dc40162e-90ef-5ef9-9070-fb671bc2e542","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 1163b97a-6fa4-4bb3-9f08-a781009188b8 --><h3>Drug interactions </h3><!-- end field 1163b97a-6fa4-4bb3-9f08-a781009188b8 -->","summary":"","htmlStringContent":"<!-- begin item b18b7681-f3f1-4511-b05f-a781009187da --><!-- begin field a9f8b39e-502f-4f9f-bf26-a781009188b8 --><ul><li><strong>Digoxin</strong> — plasma levels of digoxin are increased by ticagrelor. Monitor for adverse effects (bradycardia) and measure digoxin concentrations if necessary.</li><li><strong>Diltiazem, verapamil</strong> — concurrent use may moderately increase ticagrelor levels and cause additive bradycardia.</li><li><strong>Simvastatin </strong>— plasma concentrations of simvastatin are moderately increased by ticagrelor. Use a maximum of 40 mg simvastatin daily and advise people to report any unexplained muscle pain, tenderness or weakness.</li><li><strong>Increased risk of bleeding if ticagrelor is combined with other drugs that also increase the risk of bleeding.</strong> Examples include: <ul><li>Other antiplatelet drugs — aspirin, clopidogrel, or prasugrel.</li><li>Nonsteroidal anti-inflammatory drugs (NSAIDs) — ibuprofen, diclofenac.</li><li>Oral and parenteral anticoagulants — warfarin, heparin, dabigatran.</li><li>Selective serotonin reuptake inhibitors (SSRIs) — fluoxetine, sertraline.</li><li>Serotonin and noradrenaline reuptake inhibitors (SNRIs) — venlafaxine, duloxetine.</li></ul></li><li><strong>Drugs which when taken concurrently with ticagrelor may increase the antiplatelet effect include:</strong><ul><li>Antifungals (itraconazole, ketoconazole, voriconazole) — concurrent use is contraindicated.</li><li>Ciclosporin — monitor for ticagrelor adverse effects.</li><li>Clarithromycin, telithromycin — concurrent use is contraindicated.</li><li>HIV protease inhibitors (atazanavir and ritonavir) — concurrent use is contraindicated. </li><li>Grapefruit juice — be alert for ticagrelor adverse effects and advise the person to avoid grapefruit juice if necessary.</li><li>Quinidine — monitor for ticagrelor adverse effects.</li></ul></li><li><strong>Drugs which when taken concurrently with ticagrelor may reduce the antiplatelet effect include:</strong><ul><li>Carbamazepine.</li><li>Efavirenz.</li><li>Phenytoin.</li><li>Phenobarbital.</li><li>Rifampicin.</li><li>St John’s Wort.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>]</p><!-- end field a9f8b39e-502f-4f9f-bf26-a781009188b8 --><!-- end item b18b7681-f3f1-4511-b05f-a781009187da -->","subChapters":[]},{"id":"bde06712-8166-5877-aee1-e6a205b6e5a2","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field 0521bedd-a191-4eaf-a065-a8e8010bde79 --><h3>Monitoring</h3><!-- end field 0521bedd-a191-4eaf-a065-a8e8010bde79 -->","summary":"","htmlStringContent":"<!-- begin item a6fa85d4-ce78-44cb-a586-a8e8010bdd15 --><!-- begin field bd44397c-847f-4275-aea0-a8e8010bde79 --><ul><li>Monitor renal function one month after starting treatment.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>]</p><!-- end field bd44397c-847f-4275-aea0-a8e8010bde79 --><!-- end item a6fa85d4-ce78-44cb-a586-a8e8010bdd15 -->","subChapters":[]},{"id":"03b96cb6-ae9a-555a-a313-7ea769cb6305","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 04a5bf97-1a9a-41b2-9350-a8e8010c48f1 --><h3>Pregnancy and breastfeeding</h3><!-- end field 04a5bf97-1a9a-41b2-9350-a8e8010c48f1 -->","summary":"","htmlStringContent":"<!-- begin item d36a2e04-af5b-4edc-8666-a8e8010c45af --><!-- begin field 1d7ccd8e-faa7-4feb-a04f-a8e8010c48f1 --><h4>Pregnancy</h4><ul><li>Ticagrelor is not recommend for use in women who are pregnant.</li></ul><h4>Breastfeeding</h4><ul><li>Ticagrelor is excreted in breastmilk and a risk to newborns cannot be excluded. The manufacturer advises that ticagrelor should be avoided in women who are breastfeeding.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>]</p><!-- end field 1d7ccd8e-faa7-4feb-a04f-a8e8010c48f1 --><!-- end item d36a2e04-af5b-4edc-8666-a8e8010c45af -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}